Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 1384 results for primary care

  1. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTE13)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections....

  2. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

  3. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  4. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  5. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

  6. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  7. Using NICE guidance in social work

    A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.

  8. Using NICE guidance in social work

    A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.

  9. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

  10. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  11. Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)

    Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults.

  12. Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

    Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.

  13. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.

  14. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

    Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.